Ketamine
Viewing r1 — Apr 20, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
Ketamine — special K, ket, vitamin K — is a synthetic dissociative of the arylcyclohexylamine class. It is a shorter-acting derivative of phencyclidine (PCP), distinguished by its clinical safety profile and therapeutic versatility. Ketamine is a noncompetitive NMDA receptor antagonist, producing its effects by blocking glutamate signaling in a use-dependent manner that preferentially suppresses hyperactive neural circuits.[1]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
phencyclidine, methoxetamine, deschloroketamine +2 morephencyclidine, methoxetamine, deschloroketamine, 2-fluorodeschloroketamine, nitrous oxide show less
Synthesized by Calvin Stevens in 1962 and FDA-approved as an anesthetic in 1970, ketamine served as a battlefield agent in Vietnam before entering recreational and psychiatric contexts.[2] A landmark 2006 trial demonstrated rapid antidepressant effects in treatment-resistant depression,[3] leading to FDA approval of esketamine (Spravato) for depression in 2019.[4] It is now a Schedule III controlled substance in the United States, widely used in both clinical anesthesia and off-label psychiatric treatment.
Subjective effects include depersonalization, derealization, time alteration, bodily dissociation, and analgesia. The experience is one of progressive disconnection — sensory input arrives but fails to cohere, producing a floating detachment that deepens toward complete severance from external reality at higher doses. Nausea, confusion, amnesia, and motor impairment are characteristic unsought effects.
Psychological dependence liability is high, driven by short duration and dopamine reward circuit activation.[5][6] Acute toxicity is low — sole-agent fatality is rare[7] — but chronic use produces devastating urinary tract damage,[8] liver injury, and neurocognitive impairment.[9] Ketamine is among the most extensively studied psychoactive substances, with six decades of clinical data and an active research programme spanning anesthesiology, psychiatry, and neuroscience.
History[edit]
Discovery
Ketamine emerged from Parke-Davis's search for a safer alternative to phencyclidine (PCP), which produced unacceptable emergence psychosis in anesthetic patients. In 1962, organic chemist Calvin Stevens at Wayne State University synthesized the compound designated CI-581 — combining ketone and amine groups that would give it its name.[2] First administered to humans on August 3, 1964, at Jackson Prison, Michigan, by Guenter Corssen and Edward Domino, the compound produced a novel cataleptic state with profound analgesia and preserved reflexes — a profile Domino's wife Toni named "dissociative anesthesia".[2]
Clinical and scientific significance
FDA approval as Ketalar came in 1970, and ketamine was immediately deployed as a field anesthetic in the Vietnam War — its cardiovascular stability, wide safety margin, and intramuscular route made it uniquely suited to battlefield conditions.[2] In the 1980s, David Lodge's team documented NMDA blockade as ketamine's mechanism, linking dissociative anesthesia to glutamate neuroscience.[1] The 2006 Zarate trial then demonstrated rapid-onset antidepressant effects in treatment-resistant depression — onset within hours rather than weeks — catalyzing an entirely new direction in psychiatric pharmacology.[3]
Recreational use and regulation
Recreational use escalated from the late 1970s following accounts of psychedelic self-experimentation by Marcia Moore and John Lilly, establishing ketamine in club and rave cultures through the 1980s and 1990s.[2] The US DEA classified ketamine as Schedule III in 1999; the UK upgraded it from Class C to Class B in 2015.[2] Recognition of ketamine-induced uropathy in 2007 fundamentally altered the chronic risk calculus,[8] while FDA approval of esketamine (Spravato) in 2019 expanded legitimate medical use into psychiatry.[4]
The name "ketamine" derives from its molecular components: ketone + amine. Street nomenclature — "K," "special K," "vitamin K," "ket" — reflects its ubiquity rather than any particular cultural mythology. Unlike psychedelics associated with spiritual traditions, ketamine's cultural identity formed primarily in electronic music scenes and clinical waiting rooms — two worlds that rarely overlap but share the compound. The "K-hole" — slang for a state of complete dissociative immersion at high doses — entered drug culture vocabulary in the 1990s and remains the substance's most recognizable experiential landmark.
Chemistry[edit]
Structural class
Ketamine belongs to the arylcyclohexylamine family, defined by an aryl ring bonded to a cyclohexylamine core. It was derived from phencyclidine (PCP) by replacing PCP's piperidine ring with a methylamine group, adding a chlorine atom to the phenyl ring, and introducing a ketone to the cyclohexane ring. These modifications — particularly the 2-oxo group — shorten the duration of action from hours to minutes while preserving the NMDA channel-blocking mechanism.
Other members of this structural series include methoxetamine (MXE), deschloroketamine, and 2-fluorodeschloroketamine (2-FDCK). All share the arylcyclohexylamine scaffold and produce dissociative effects through NMDA antagonism, differing primarily in potency, duration, and secondary receptor activity.
Molecular identity
| Molecular formula | C₁₃H₁₆ClNO |
| Molecular weight | 237.72 g/mol |
The core structure comprises a cyclohexanone ring bearing a methylamino group and a 2-chlorophenyl ring at the 2-position. The chlorine substituent contributes to the compound's lipophilicity and ability to cross the blood-brain barrier rapidly.
Stereochemistry
Ketamine has a single chirality center at C-2 of the cyclohexanone ring, producing two mirror-image forms:
- S-ketamine (esketamine): approximately 4× more potent as an anesthetic than the R-form and approximately 2× more effective than the racemic mixture.[10] FDA-approved as Spravato (intranasal) for treatment-resistant depression.
- R-ketamine (arketamine): less potent at the NMDA receptor[11] but shows potentially lower abuse liability. Under clinical investigation as a next-generation antidepressant.
Clinical Ketalar contains a 1:1 mixture of both forms. The distinct pharmacological profiles of the enantiomers have driven development of single-enantiomer formulations for specific therapeutic applications.
Pharmacology[edit]
Mechanism of action
Ketamine blocks the NMDA by entering the ion channel pore after glutamate has opened it — a "use-dependent" mechanism meaning blockade intensifies wherever neural circuits are most active.[1] This produces functional disconnection between brain regions: sensory information reaches primary cortex but fails to integrate with higher processing areas, generating the dissociative state.
At lower doses, a paradoxical effect occurs. NMDA blockade on inhibitory interneurons releases a brake on excitatory neurons, flooding the prefrontal cortex with glutamate.[12] This glutamate surge drives both the psychotomimetic effects and the rapid antidepressant mechanism — activating growth pathways that rebuild stress-damaged synapses within hours.[13]
The antidepressant mechanism involves multiple convergent pathways: direct NMDA blockade triggering synapse growth via the mTOR pathway,[13][14] AMPA activation by the hydroxynorketamine metabolite,[15] and opioid system engagement — naltrexone pretreatment abolishes the antidepressant response without affecting dissociation.[16] The relative contributions of these pathways remain actively debated.
As an analgesic, ketamine reduces central pain sensitization at concentrations approximately 10× lower than those required for anesthesia,[1] supporting clinical use of sub-dissociative doses for pain management.
Pharmacokinetics
Bioavailability varies dramatically by route: intravenous delivers 100%, intramuscular approximately 93%, intranasal approximately 50%,[4] and oral only 17–26% due to extensive first-pass liver metabolism.[17][18] This first-pass metabolism converts most oral ketamine to norketamine before it reaches the brain, producing a qualitatively different pharmacological profile than parenteral routes.
The liver enzymes CYP3A4 and CYP2B6 metabolize ketamine to norketamine, which is further converted to hydroxynorketamine (HNK).[10][19] The oral route produces far higher HNK-to-ketamine ratios than intravenous dosing,[20] a finding with implications for why oral ketamine may work differently as an antidepressant.
Drug interactions affecting metabolism are clinically significant: the antibiotic rifampicin reduces oral ketamine exposure by 86%,[21] while enzyme inhibitors may intensify and prolong effects. S-ketamine is approximately 4× more potent than R-ketamine as an anesthetic,[10] and following oral dosing, 80% of S-ketamine undergoes first-pass conversion to S-norketamine.[17]
Neuroscience[edit]
Where it acts
Ketamine disrupts communication between the thalamus (the brain's sensory relay) and the cortex (where information is interpreted). Sensory data still arrives at primary receiving areas but fails to integrate with associative networks[1] — producing the subjective experience of perceiving fragments without coherent meaning. At subanesthetic doses, the prefrontal cortex receives a paradoxical glutamate flood as inhibitory interneurons are silenced,[12] driving both cognitive disruption and the rapid synapse-building that reverses depressive neural atrophy.[13][14]
Why it matters
Ketamine demonstrated that depression could be reversed in hours rather than weeks — a finding that upended assumptions about antidepressant mechanisms. The dominant framework holds that NMDA blockade on interneurons triggers a glutamate surge, activating AMPA receptors and the mTOR growth pathway to rapidly rebuild stress-damaged synapses in the prefrontal cortex.[13] A competing model proposes that the metabolite hydroxynorketamine drives sustained effects through AMPA activation independent of NMDA blockade.[15] A third finding — that opioid blockade abolishes the antidepressant response[16] — suggests opioid engagement is also required. These frameworks may reflect distinct temporal phases rather than mutually exclusive mechanisms.
Why does a drug with a 2–3 hour half-life produce antidepressant effects lasting days to weeks? Synaptogenesis provides a structural explanation, but the relationship between transient receptor occupancy and sustained remodeling remains incompletely characterized. Whether chronic recreational use causes irreversible neurocognitive damage in humans is unresolved: primate studies show permanent prefrontal cell death after 6 months,[9] and human chronic users show cognitive impairment consistent with schizophrenia-like profiles,[22] but confounders cannot be fully controlled.
Subjective Effects[edit]
Ketamine produces a progressive dissolution of the ordinary relationship between self and world. At lower doses, perception softens and distances — the body feels remote, sounds flatten, and a pleasant floaty weightlessness dominates. As dose increases, the experience shifts qualitatively rather than merely intensifying: coherent selfhood fragments, spatial orientation collapses, and at strong doses the external world vanishes entirely into abstract internal space. This steep dose-response curve — from mild pleasant dissociation to complete disconnection across a narrow range — makes precise measurement essential. Set and setting powerfully modulate the character: quiet, dark environments facilitate immersive internal exploration, while stimulating settings tend to produce disorientation and confusion rather than depth.
Within its class, ketamine occupies a middle position: shorter and more controllable than PCP or MXE, deeper and more amnestic than nitrous oxide. Route matters as much as dose — insufflation produces a rapid, sharp onset, intramuscular injection a forceful wave, while oral dosing generates a gentler arc with a qualitatively warmer character dominated by the norketamine metabolite.
Effect Grid
At common doses, the characteristic dissociative experience fully manifests: significant depersonalization and derealization, time distortion, and perceptual distortions including visual drifting, auditory distortions, and altered depth perception. Thought connectivity changes dramatically — internal experiences become vivid and absorbing. Euphoria is frequently reported, alongside a sense of profound meaningfulness.
Physically, pronounced analgesia, significant motor impairment (difficulty walking), nystagmus, and muscle relaxation are universal. Speech becomes markedly impaired. Nausea is possible but less common than with serotonergic psychedelics.
Ambulation is unsafe at this range. The experience typically demands full surrender to the dissociative state for 45-90 minutes (IV/IM/insufflated) or 2-3 hours (oral).
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Perspective distortion · Proprioceptive distortion · Vestibular distortion · Holotropic state · Sensory deprivation · Visual acuity suppression · Music enhancement · Visual haze / noise · Auditory suppression · Visual drifting · Auditory misinterpretation · Geometry · Peripheral vision distortion · Color alteration · Tracers · Visual morphing · Synesthesia · Dreaming enhancement · Visual processing suppression · Internal hallucinations · Auditory hallucinations · Environmental orbism / cubism · Object transformations · Perspective hallucinations · Visual scenery slicing · External hallucinations · Visual recursion · Gustatory hallucination
Sensory deprivation · Visual acuity suppression · Music enhancement · Visual haze / noise · Auditory suppression · Visual drifting · Auditory misinterpretation · Geometry · Peripheral vision distortion · Color alteration · Tracers · Visual morphing · Synesthesia · Dreaming enhancement · Visual processing suppression · Internal hallucinations · Auditory hallucinations · Environmental orbism / cubism · Object transformations · Perspective hallucinations · Visual scenery slicing · External hallucinations · Visual recursion · Gustatory hallucination
Body high · Nystagmus (eye wobbles) · Spontaneous body sensations · Bodily lightness · Pupil dilation · Dizziness · Physical fatigue · Nausea · Stimulation · Abnormal heartbeat · Salivation · Sexual arousal suppression · Heart rate perception changes · Muscle relaxation · Nasal congestion · Respiratory stimulation · Dehydration sensation · Breathing alteration · Dry mouth · Headache · Laughter fits · Temperature dysregulation · Tingling / electric sensations · Vibrations / buzzing · Tactile euphoria · Involuntary body movements · Restlessness · Trembling · Vomiting · Increased urination · Bodily dissociation · Tactile hallucination
Bodily lightness · Pupil dilation · Dizziness · Physical fatigue · Nausea · Stimulation · Salivation · Sexual arousal suppression · Heart rate perception changes · Muscle relaxation · Nasal congestion · Respiratory stimulation · Dehydration sensation · Breathing alteration · Dry mouth · Headache · Laughter fits · Temperature dysregulation · Tingling / electric sensations · Vibrations / buzzing · Tactile euphoria · Involuntary body movements · Restlessness · Trembling · Vomiting · Increased urination · Bodily dissociation · Tactile hallucination
Thought disorganization · Confusion · Analysis suppression · Information processing suppression · Memory fragmentation · Thought deceleration · Pattern recognition suppression · Language suppression · Immersion enhancement · Introspection enhancement · Conceptual thinking · Cognitive euphoria · Compulsive redosing urge · Cognitive fatigue · Cognitive flexibility · Motivation suppression · Openness enhancement · Thought loops · Creativity enhancement · Humor enhancement · Cognitive dysphoria · Amnesia · Delusions · Delirium
Information processing suppression · Memory fragmentation · Thought deceleration · Pattern recognition suppression · Language suppression · Immersion enhancement · Introspection enhancement · Conceptual thinking · Cognitive euphoria · Cognitive fatigue · Cognitive flexibility · Motivation suppression · Openness enhancement · Thought loops · Creativity enhancement · Humor enhancement · Cognitive dysphoria · Amnesia · Delusions · Delirium
Emotional enhancement · Anxiety · Emotional lability · Emotional suppression · Catharsis · Dysphoria · Irritability
Catharsis · Dysphoria · Irritability
Disinhibition · Sociability suppression · Craving · Compulsive behavior reduction · Ego inflation · Cognitive disconnection · Ego dissolution · Identity alteration · Boundary dissolution
Ego inflation · Cognitive disconnection · Ego dissolution · Identity alteration · Boundary dissolution
Death-rebirth sequence · Entity contact · Existential realization · Noetic insight · Non-dual awareness · Transpersonal visions
Non-dual awareness · Transpersonal visions
Timeline
First effects emerge 15-30 minutes after ingestion: subtle mood shift, mild warmth, and early hints of dissociation as ketamine and norketamine begin reaching active concentrations.
Dissociation builds gradually over 15-30 minutes. The oral come-up is gentler than insufflated, with progressive deepening rather than rapid onset. Analgesia and motor impairment develop.
Maximum intensity sustained 45-90 minutes. Norketamine contributes significantly to the oral peak, producing a somewhat warmer, less sharp dissociative character than parenteral routes.
Extended plateau phase (45-90 minutes) due to sustained norketamine and HNK metabolite activity. Dissociation gradually lightens while dreamy cognitive quality persists.
Effects gradually resolve over 30-60 minutes. Motor function returns. Mild residual dissociation and analgesia taper.
Residual effects from active metabolites (norketamine, HNK) may persist 2-8 hours as subtle mood effects, mild cognitive blunting, or perceptual softness. Antidepressant effects may emerge during this period.
⚠ Do not drive or operate machinery until the following day, as metabolite-mediated impairment outlasts subjective awareness of primary effects.
Safety[edit]
- Acute toxicity
- Low
- Chronic toxicity
- High
- Withdrawal
- Moderate
- Tolerance buildup
- moderate
- Tolerance reset
- 4 weeks
- Physical
- Moderate
- Psychological
- High
- Compulsive redosing
- High
- Dose escalation
- High
- Cross-tol.
- phencyclidine · methoxetamine · deschloroketamine
Toxicity
Acute toxicity
Ketamine has a wide margin between anesthetic and lethal doses. Unlike most general anesthetics, it preserves airway reflexes, spontaneous breathing, and cardiovascular stability — and produces mild blood pressure elevation rather than depression.[10][7] Sole-agent death is documented but extremely rare; virtually all ketamine-related fatalities involve combination with opioids or other depressants.[23]
No human lethal dose has been established. The wide safety margin as a sole agent makes pure ketamine overdose death mechanistically difficult absent choking on vomit or trauma during impaired consciousness.
Urinary tract damage (chronic)
Ketamine-induced bladder damage is the most significant chronic toxicity in regular users. Frequent use increases cystitis risk 3–4×.[24] End-stage contracted bladder may be irreversible.[25]
Regular ketamine use damages the bladder lining through multiple pathways: direct cell death in bladder tissue,[26] toxic effects from the norketamine metabolite,[27] and disruption of calcium channels in bladder muscle.[28] Symptoms include urinary frequency, urgency, pain, and blood in urine. Early-stage damage may improve with complete cessation. Advanced disease — a shrunken, scarred bladder — requires surgical reconstruction.[25]
Liver and bile duct damage (chronic)
Chronic use can produce bile duct inflammation resembling a scarring liver disease,[29] bile duct dilation,[30] and direct liver cell damage.[31][32] Abnormal liver enzymes have been documented even in clinical settings with repeated high-dose infusions.[31] Liver markers typically normalize within 2 months of stopping.
Brain damage (chronic)
Six months of subanesthetic ketamine in primates produces permanent brain cell death in the prefrontal cortex.[9] Human chronic users show memory suppression and cognitive profiles resembling schizophrenia.[22][33] Some white matter changes partially reverse with abstinence.[1]
Psychological risks
Ketamine produces dose-related psychosis-like symptoms: perceptual distortions, paranoia, and withdrawal from interaction.[34] In people with schizophrenia, 70% experienced worsening of symptoms at subanesthetic doses.[34] These effects resolve within 30 minutes of a single dose.
Emergence phenomena — vivid dreams, delirium, confusion — occur during recovery from anesthetic doses. Heavy chronic use can trigger persistent psychotic symptoms in a minority of users, with cognitive profiles indistinguishable from schizophrenia.[33]
Tolerance and dependence
Tolerance develops gradually with repeated use through changes in NMDA density and glutamate signaling. Cross-tolerance exists with other NMDA-blocking dissociatives: PCP, MXE, deschloroketamine, 2-FDCK, and nitrous oxide. Dose escalation is a consistent feature of chronic use, and extended abstinence is required for tolerance reversal.
Psychological dependence liability is high.[6] The combination of rapid reward, short duration encouraging redosing, and dopamine activation in reward circuits[5] creates a profile highly conducive to compulsive use. Opioid receptor engagement may provide additional reinforcement.[16]
Physical dependence is moderate. Withdrawal is distressing but not life-threatening,[35] involving dysphoria, cravings, and disrupted sleep and stress hormones.[36]
Drug interactions
The most dangerous ketamine combinations involve additive depression of breathing and consciousness.
Opioids (potentially lethal): Despite ketamine's preservation of respiratory drive alone, combination with opioids produces additive or synergistic respiratory depression. This is the primary mechanism of ketamine-related death — virtually all documented fatalities involve opioids or other depressants.[23] All full μ-opioid agonists carry this risk: fentanyl, heroin, morphine, oxycodone, methadone.
GHB/GBL and alcohol (potentially lethal): Additive depression of consciousness with cardiovascular instability and choking risk during unconsciousness.
CYP3A4/CYP2B6 interactions: Enzyme inducers (rifampicin, carbamazepine) can reduce oral ketamine effectiveness by up to 86%.[21] Enzyme inhibitors may prolong and intensify effects, particularly by the oral route.
MAOIs: Unlike serotonergic drugs, ketamine does not carry serotonin syndrome risk with MAOIs. Blood pressure elevation from sympathomimetic synergy remains a theoretical concern but appears minimal in practice.citation needed
Contraindications
- Uncontrolled high blood pressure or severe heart disease: Ketamine's stimulant-like cardiovascular effects add further stress[10][7]
- History of psychosis or schizophrenia: Ketamine worsens psychotic symptoms; 70% of schizophrenic patients experienced exacerbation in controlled studies[34]
- Pre-existing bladder disease: Risk of accelerated damage in already-compromised urinary tissue
- Active liver disease: Altered metabolism and increased toxicity risk[31]
- Overactive thyroid: Additive cardiovascular stimulation
- Pregnancy: Precautionary exclusionsafety citation needed
- Co-administration with opioids or depressants: Primary mechanism of ketamine-related death[23]
Harm Reduction[edit]
Forms & Identification
Ketamine's clinical origin means pharmaceutical-grade product exists alongside illicitly manufactured powder — but quality varies enormously in unregulated markets. Diverted pharmaceutical liquid (clear, odorless, from sealed vials) offers a baseline purity guarantee that dried powder cannot. The powder form most commonly encountered has been evaporated from liquid, a process that may concentrate impurities or introduce contaminants.
Reagent testing confirms identity but not purity or dose. Quantitative testing (FTIR, lab analysis via services like WEDINOS or DrugsData) provides the strongest confidence. Fentanyl test strips are worth using given the contamination patterns in stimulant and depressant markets, though ketamine adulteration with fentanyl remains less common than in opioid or cocaine supply.
Guidelines
- Test every batch. Reagent testing confirms identity; quantitative analysis confirms dose.
- Weigh doses precisely. The transition from pleasant to overwhelming spans a narrow range. A milligram scale (0.001g) is essential for insufflated powder.
- Start low with new batches. Potency varies between sources; take a threshold dose first.
- Time redoses carefully. Short duration encourages compulsive redosing — the primary dependence pathway. Set a firm limit before starting and use timers.
- Separate ketamine sessions. Regular use causes cumulative bladder damage. Spacing sessions by at least 1–2 weeks and ideally longer reduces chronic harm.
- Eat lightly or fast beforehand. Nausea and vomiting risk increases with stomach contents; choking risk exists at high doses when unconscious.
- Avoid mixing with depressants. Opioids, alcohol, GHB/GBL, and benzodiazepines compound respiratory depression and choking risk.
- Stay hydrated. Adequate water intake may help protect the urinary tract during and after use.
Set & Setting
Ketamine's dissociative character makes environment unusually important. A quiet, comfortable space with minimal stimulation — dim lighting, familiar surroundings, soft surfaces — supports immersive, controllable experiences. Stimulating or unfamiliar environments (clubs, crowds, outdoors near water or traffic) increase confusion and physical risk during motor impairment.
A sober companion is strongly recommended at doses approaching or exceeding the "K-hole" threshold. Complete disconnection from external reality means the user cannot respond to environmental dangers. Physical safety (no heights, no water, recovery position if lying down) matters more than psychological reassurance at dissociative depths.
Aftercare & integration. Ketamine's dissociative depth can produce experiences that feel profoundly meaningful, bizarre, or disturbing. Processing is appropriate regardless of whether the experience was sought therapeutically or recreationally.
In the hours after: gentle re-grounding through familiar sensory input (warm drinks, soft textures, quiet conversation), light food, and rest. Motor coordination and judgment may remain subtly impaired for several hours beyond perceived sobriety. Avoid driving or complex decisions.
For intense or difficult experiences: writing or drawing the experience within 24 hours helps integration before memory consolidation fades the details. Persistent derealization, emotional flatness, or intrusive memories lasting more than a few days warrant professional support — particularly from therapists familiar with dissociative states.
Recovery & Support
Ketamine dependence develops insidiously. The pattern — short duration, immediate reward, easy redosing — can escalate from occasional to daily use without a clear threshold moment. Early signs include dose escalation, using alone, prioritizing supply, and urinary symptoms.
Tapering with professional support is more effective than abrupt cessation for heavy users. Withdrawal is not physically dangerous but involves significant psychological distress: cravings, low mood, insomnia, and cognitive fog that may persist for weeks.
Specialist support resources include drug and alcohol services experienced with dissociative dependence, peer support communities, and — for urinary damage — urology referral. Bladder symptoms should prompt immediate medical attention and complete cessation; early-stage damage can still recover, but continued use after symptom onset dramatically worsens prognosis.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency:
- Unconsciousness with vomiting (choking risk)
- Blue or grey lips/fingernails (oxygen deprivation)
- Extremely slow or stopped breathing
- Seizure
- Chest pain or irregular heartbeat
- Severe confusion with self-harm behavior
An immobile person in a K-hole who is breathing normally and not vomiting is uncomfortable but not in medical danger. The above signs indicate something has gone wrong — often a drug combination.
Immediate steps:
- Call emergency services if breathing is compromised, person is unresponsive to sternal rub, or any sign of choking
- Place in recovery position (on side, mouth angled downward) to prevent choking
- Clear airway of vomit if present
- Monitor breathing continuously
- Do NOT leave the person alone
- Do NOT induce vomiting
- Do NOT restrain unless immediate physical danger (near traffic, water, heights)
What to tell the dispatcher: Substance taken (ketamine, plus anything else), approximate amount, time of last dose, current symptoms, and whether any other drugs were involved. Good Samaritan laws in many jurisdictions protect callers from prosecution when seeking medical help.
Legal Status[edit]
International framework
Ketamine is not listed under any of the three UN international drug control conventions. The WHO Expert Committee on Drug Dependence has repeatedly recommended international scheduling; the UN Commission on Narcotic Drugs has rejected these recommendations — largely at the urging of nations concerned about restricting access in low-resource healthcare settings where ketamine serves as an essential anesthetic.[2][37]
This creates an unusual regulatory position: a widely misused substance with no international scheduling, controlled exclusively through national legislation.
Jurisdiction table
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Schedule III (Controlled Substances Act) | Classified 1999; medical use as Ketalar (1970) and Spravato (2019) maintained[2][4] |
| United Kingdom | Class B, Schedule 2 (Misuse of Drugs Act 1971) | Reclassified from Class C to Class B in January 2015 |
| Australia | Schedule 8 (Controlled Drug) | Strict prescription requirementscitation needed |
| Canada | Schedule I (CDSA) | Controlled Drugs and Substances Actcitation needed |
| China | Category I psychotropic drug | Since 2004; reflects scale of recreational use in mainland China and Hong Kong[2] |
| European Union | No EU-harmonized scheduling | Member states apply national legislation; most classify equivalent to Schedule II/III controls |
Regulatory notes
Ketamine occupies a unique position as a WHO Essential Medicine simultaneously subject to national drug control. The tension between preserving access (particularly in veterinary medicine and low-resource anesthesia) and preventing misuse has blocked international consensus on scheduling. FDA approval of esketamine for depression in 2019 expanded legitimate medical use while raising concerns about diversion from supervised clinical settings.
references
- [1]
- [2]
- [3] ^abZarate CA, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, Charney DS, Manji HK (2006) A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression — Archives of General Psychiatry PMID:16894061
- [4] ^abcdvan Hoogdalem MW, Fu DJ, Drevets WC, Zannikos PN (2026) Esketamine Nasal Spray: Mechanism of Action, Clinical, and Translational Science — Clinical and Translational Science doi:10.1111/cts.70527
- [5] ^abSeeman P, Ko F, Tallerico T (2005) Dopamine receptor contribution to the action of PCP, LSD and ketamine psychotomimetics — Molecular Psychiatry PMID:15852061
- [6] ^abCosci F, Chouinard G (2020) Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications — Psychotherapy and Psychosomatics doi:10.1159/000506868